• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.
By BRET JENSEN
Sep 07, 2017 | 01:00 PM EDT
Stocks quotes in this article: MYOK, AVEO, AMGN, CELG

Living in Florida for 15 years now, one comes to know the value of preparation when hurricane season is in full force. I have ridden out most of the storms that seemed headed our way over the past decade and a half, taking the proper precautions to reduce risk of major damage. That strategy has worked out well over the years.

However, sometimes there is little one can do and the only recourse is to "get out of Dodge" after securing your place. Such is the case with Hurricane Irma, which is why I am up working out of a New York City hotel along with my girlfriend this week and my Golden Retriever is in the front seat of my buddy's 911 heading up to Richmond, Va.

This precaution and planning ahead in my personal life also extends to my philosophy and strategy toward investing, where I operate in a similar manner. I consider myself a cautious but prudent investor even if I largely invest in biotech and small-cap stocks.

This cautious prudence has served me well in investing over the decades. I was entirely out of the market before the Internet Bust and had more than one-third of my portfolio in cash (and not nearly enough!) before the recent financial crisis. Obviously, I am not nearly as pessimistic on the current market as either of those instances.

Nevertheless, I do believe the current market is fully, if not at least slightly overvalued and bargains are hard to find. Stocks have had a good year despite increasing dysfunction in D.C., dimming prospects for tax reform and major infrastructure spending as well as escalating global tensions around North Korea. Most of the gains have come from large-cap concerns, especially in technology.

While still finding the occasional undervalued small-cap, I am not seeing many compelling names now. Therefore, I have slowly and incrementally raised my cash allocation to just over 20% of the portfolio.

How have I done this? Largely by culling profits, using the "Jensen Rules" (see below), from some of my small-cap biotechs that have had huge runs in 2017. These include MyoKardia Inc. (MYOK) and AVEO Pharmaceuticals (AVEO) . I also used last week's big surge in the biotech sector to sell some out-of-the-money covered calls on parts of core holdings Amgen (AMGN) and Celgene Corp. (CELG) for solid premiums.

I am not expecting a major pullback in 2017, although a 5% "hiccup" seems long overdue. I also don't see how we get a significant rally from here, unless tax reform efforts bear major fruit, which does not seem likely.

And that is how I am prudently playing the market while praying I have a place to come back to in Miami when Irma has come and gone. For all in the Hurricane's path, please take the proper measures to keep and your family safe.

The "Jensen Rules"

If you buy 1,000 shares of a small cap stock:

  • If the equity goes up 50%, sell 100 shares.
  • If the stock doubles, sell another 200 shares.
  • If the shares triple, sell another 200 shares.

You now have locked in a guaranteed profit even if the stock goes to zero. You also have 50% of the original stake riding on the "house's money", one of the best free rides there is.

This commentary originally appeared on Real Money Pro. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication Jensen was long AMGN, AVEO, CELG and MYOK.

TAGS: Investing | U.S. Equity | Healthcare | Markets | Economy | How-to | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login